Impact Analysis of Covid-19 The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters. Request Sample

Flow Cytometry Market – It’s not just for immunologist anymore

The requisite for disease diagnosis and advancements in technology of flow cytometry, in turn are expected to fuel growth of the flow cytometry market over the forecast period. Manufacturers are focusing on technological innovations in flow cytometry to tap into the emerging markets. For instance, in August 2017, Beckman Coulter Life Sciences received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its latest clinical flow cytometry product, the Navios EX flow cytometer, to be used in the clinical laboratories in the U.S. Furthermore, Sysmex America, Inc. in October 2017, launched CyFlow Antibodies, a comprehensive portfolio of Analyte Specific Reagent (ASR) antibodies for usage in flow cytometry applications, as a part of its initiative to offer cutting-edge clinical laboratory products.

Moreover, major players are focusing on the product launches for enhancing their product portfolio and to strengthen their market positions. For instance, in June 2019, Becton, Dickinson and Company (US) launched its FlowJo software version 10.6 for flow cytometry data analysis that can be further integrated with BD FACSDiva for enhancing its capabilities to analyze multiple flow cytometry runs and compare data in a single view.

The global flow cytometry market was valued at US$ 3,886.1 million in 2018 and is expected to exhibit a CAGR of 10.2% over the forecast period (2019-2027).

Figure 1. Global Flow Cytometry Market Value (US$ Mn), by Region, 2018

Source: Coherent Market Insights Analysis (2020)

Introduction of new products by the major players is expected to drive growth of the market over the forecast period.

Major market players are focused on product launches in the market, which is expected to boost the market growth over the forecast period. For instance, in March 2017, Cytek Biosciences Inc., a manufacturer and supplier of flow cytometry products and services launched its DxP Athena flow cytometry system. The system is compact, powerful, easy-to-use cell analyzer that are typically only found in conventional instruments that come with a much higher price tag. The DxP Athena makes the benefits of flow cytometry which are more readily available to larger number of researchers by its compact size.

Furthermore, in April 2018, Merck KGaA launched its new Cell Stream benchtop flow cytometry system, a compressed, customizable flow cytometer that uses a camera for detection of the specimen. It is a unique optics system and this design offers researchers with unparalleled sensitivity and flexibility, when analyzing cells and submicron particles. This launch helped the company to expand its product line in flow cytometers.

Figure 2. Global Flow Cytometry Market Share (%), by Technology,2019 and 2027

Source: Coherent Market Insights Analysis (2020)

Global Flow Cytometry Market- Regional Insights

North America is expected to hold a dominant position in the market, owing to large healthcare industry in the region. To retain its position in the market, key players are focused on launching new products in the region. For instance, in September 2017, Beckman Coulter, Inc. (U.S.), launched their first flow cytometry CytoFLEX LX for the cancer researchers, which has the visible spectrum in a standard configuration. This launch helped in expanding its business in flow cytometry.

Moreover, Europe is expected to hold the second largest market share over the forecast period, owing to product launches in the European market. For instance, In September2017, Miltenyi Biotec GmbH (Germany) launched a fully automated high-throughput flow cytometry MACSQuant X which handles 384-well plates in less than 60 minutes giving users fast, reliable, and reproducible results. Launching these products has expanded the flow cytometry product line of company.

Moreover, Asia Pacific is expected to witness significant growth in the market, owing to rising cases of cancers in the region. For instance, according to the World Health Organization (WHO), in 2018, there were 3.9 million number of prevalent cases for cancers and 2.0 million number of new cancer cases are reported each year in the Asia Pacific.

Key Players

Major players operating in the global flow cytometry market include Becton Dickinson and Company, General Electric Company, Luminex Corporation, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Miltenyi Biotec GmbH, Merck & Co Inc., Sysmex Corporation, Agilent Technologies, Inc., and Danaher Corporation.